MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 22, 2005; DOI: 10.1124/mol.104.010470


0026-895X/05/6706-2162-2172$20.00
Mol Pharmacol 67:2162-2172, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.010470v1
67/6/2162    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cheng, H.
Right arrow Articles by Hsu, W. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cheng, H.
Right arrow Articles by Hsu, W. H.

Somatostatin Increases Phospholipase D Activity and Phosphatidylinositol 4,5-bisphosphate Synthesis in Clonal {beta} Cells HIT-T15

Henrique Cheng, Justin A. Grodnitzky, Sirintorn Yibchok-anun, Jing Ding, and Walter H. Hsu

Department of Biomedical Sciences, Iowa State University, Ames, Iowa

In the presence of arginine vasopressin (AVP), somatostatin increases [Ca2+]i, leading to a transient increase in insulin release from clonal {beta} cells HIT-T15 via Gi/o and phospholipase C (PLC) pathway (Cheng et al., 2002a). The present study was to elucidate the mechanisms underlying somatostatin-induced [Ca2+]i increase in the presence of AVP. We found that the effect of somatostatin was mediated by {beta}{gamma} subunits but not by the {alpha} subunit of Gi/o. Because somatostatin alone failed to increase [Ca2+]i, we hypothesized that somatostatin increases phosphatidylinositol 4,5-bisphosphate (PIP2) synthesis, providing extra substrate for preactivated PLC-{beta} to generate inositol 1,4,5-trisphosphate (IP3). Somatostatin alone did not increase IP3 levels, but AVP + somatostatin did. Somatostatin increased PIP2 levels but decreased phosphatidylinositol 4-phosphate levels. We further hypothesized that PLD mediates somatostatin-induced changes in PIP2 levels. Both the phospholipase D (PLD) inhibitors and antibody versus PLD1 antagonized AVP-somatostatin-induced increases in [Ca2+]i. PLD inhibitor also antagonized somatostatin-induced increase in PIP2 levels. In addition, somatostatin increased PLD activity. These results suggest that activation of somatostatin receptors that are coupled to the {beta}{gamma} dimer of Gi/o led to PLD1 activation, thus promoting the synthesis of phosphatidic acid. Phosphatidic acid activates PIP-5 kinase, which evokes an increase in PIP2 synthesis. The PIP2 generated by somatostatin administration increases substrate for preactivated phospholipase C-{beta}, which hydrolyzes PIP2 to form IP3, leading to an increase in [Ca2+]i. The regulation of PIP2 synthesis by Gi/o-coupled receptors via PLD activation represents a novel signaling mechanism for somatostatin and a novel concept in the cross-talk between Gq- and Gi/o-coupled receptors in {beta} cells.


Received December 19, 2004; accepted March 22, 2005

Address correspondence to: Dr. Walter H. Hsu, Department of Biomedical Sciences, Iowa State University, Ames, IA 50011-1250. E-mail: whsu{at}iastate.edu




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
J. A. Grodnitzky, N. Syed, M. J. Kimber, T. A. Day, J. G. Donaldson, and W. H. Hsu
Somatostatin Receptors Signal through EFA6A-ARF6 to Activate Phospholipase D in Clonal beta-Cells
J. Biol. Chem., May 4, 2007; 282(18): 13410 - 13418.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics